{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.5","upperLimit":"21.1","value":"16.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"310"}],"units":"Participants"}],"description":"Tumor response was assessed by the investigator according to RECIST v1.1. CR was defined as disappearance of all target and non-target lesions and (if applicable) normalization of tumor marker levels. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm. PR was defined as ≥30% decrease in sum of LD of target lesions in reference to Baseline sum LD. Response was to be confirmed ≥4 weeks after the initial assessment of CR or PR. The percentage of participants with a confirmed objective response of CR or PR was reported. The exact 95% CI was calculated using the Clopper-Pearson method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who had disease progression during or following treatment with at least one platinum-containing chemotherapy regimen in the metastatic setting received atezolizumab 1200 mg via IV infusion on Day 1 of 21-day cycles until loss of clinical benefit or unmanageable toxicity.","id":"OG000","title":"Cohort 2: Participants With Second-line or Beyond Treatments"}],"paramType":"NUMBER","populationDescription":"Cohort 2 objective response-evaluable population.","reportingStatus":"POSTED","timeFrame":"Baseline until confirmed disease progression or death, whichever occurred first (assessed at every 9 weeks for the first 12 months, thereafter every 12 weeks until data cutoff date 04 July 2016, up to maximum length of follow-up of 24.48 months)","title":"Percentage of Participants With a Confirmed Objective Response of CR or PR as Assessed by the Investigator According RECIST v1.1","type":"SECONDARY","unitOfMeasure":"percentage of participants"}